Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Abstract

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy

“…Some evidence shows that BMI is correlated with the prognosis of targeted and immunotherapy for cancer ( 11 , 19 ), but no studies have reported the prognostic role of BMI in anti-PD-1 therapy for HCC patients. In our study, BMI was shown to be an independent prognostic factor for HCC patients receiving anti-PD-1 treatment.…”

“…The body mass index (BMI), as a major indicator of body weight and nutritional status, is correlated with efficacy of many drugs ( 10 ). BMI is a useful predictor of prognosis in patients with renal cell carcinoma treated with targeted therapy ( 11 ). In metastatic melanoma, BMI may predict tumor response to ICIs ( 12 ).…”

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

“…These patients seem to be often immunocompromised, not only for the physiological age-related immune senescence, but also for the frequent history of solid organ and/or hematological stem cell transplantation, and hematological malignancies, especially B cell chronic lymphocytic leukemia ( 20 ). Notably, obesity is often accompanied by a chronic low-grade systemic inflammation ( 26 – 28 ), stimulated by the production of the pro-inflammatory cytokines, which alters the microenvironment of expanded adipose tissue. Chronic inflammation can induce immunosuppression as a result of a T cells exhaustion by persistent antigenic stimulation, ultimately inducing dysfunction of the immune system in obese patients ( 28 ).…”

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

“…23 Importantly, tumor metabolic dependencies are emerging as key tumor vulnerabilities, and patient-associated features, such as body mass index (BMI), are under investigation as factors to profoundly impact the cancer immune responses. [24][25][26][27][28] Although the mechanistic link between metabolic state and immunotherapy benefit was not elucidated, an impact of excess adiposity/obesity on the PD-1/ PD-L1 pathway seems to exist. Recent preclinical findings suggested that obesity promotes T-cell exhaustion through leptin-induced upregulation of PD-1.…”